Trial Profile

The Phase 1 clinical trial evaluated the safety, tolerability, and pharmacokinetics (PK) of single- and multiple-ascending doses of A-005 in healthy participants

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 27 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs A 005 Alumis (Primary)
Indications Multiple sclerosis; Neurodegenerative disorders; Parkinson's disease
Focus Adverse reactions; Pharmacokinetics

27 Feb 2025 According to an Alumis media release, clinical data from this study will support Phase 2 clinical trial in patients with multiple sclerosis in the second half of this year.
27 Feb 2025 Results published in the Alumis Media Release
19 Dec 2024 According to an Alumis media release, company plans to present data from this trial at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025 taking place February 27- March 1, 2025, in West Palm Beach, Florida.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com